Q-omics provides the consensus-scored NKX2-8 profile across patient tissues and cancer cell-line models. NKX2-8 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NKX2-8 is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, NKX2-8 RNA expression shows 12,912 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRP, and THYM as cancer lineages where NKX2-8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NKX2-8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NKX2-8 survival associations across molecular data types. NKX2-8 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NKX2-8 RNA expression–survival associations across cancer types. High NKX2-8 expression shows unfavorable associations in HNSC, KIRC, STAD, UVM and UCEC, but favorable associations in READ. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for NKX2-8 RNA expression.
This table summarizes NKX2-8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NKX2-8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NKX2-8 shows lower tumor expression in BRCA and LUAD and higher tumor expression in KIRP, KIRC, BLCA and UCEC. The KIRP box plot shows higher NKX2-8 RNA expression in tumor versus normal tissue (log2 FC = +0.780, t-test p = .008).
This table shows molecular features associated with NKX2-8 in patient tissues and cancer cell lines. In patient samples, NKX2-8 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NKX2-8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
